by Richard Daverman, PhD
October 1, 2012 -- Sanofi and Sinopharm (China State Institute of Pharmaceutical Industry) signed a MOU in Shanghai to conduct joint research into rare diseases. Although details haven’t been released, the collaboration will apparently survey the incidence of rare diseases in China, then seek to understand causes and find treatments. In 2011, Sanofi paid $20 billion to acquire US-based Genzyme, a specialist in rare diseases. More details....
Stock Symbol: (NYSE: SNY)
